ESE‑1 suppresses the growth, invasion and migration of human NSCLC cells and tumor formation in vivo

Lou,Zhiyuan; Lee,Bok‑Soon; Ha,Taekyu; Xu,Yanrui; Kim,Haeng‑Jun; Kim,Chul‑Ho; Lee,Seong‑Ho

doi:10.3892/or.2018.6560

ESE‑1 suppresses the growth, invasion and migration of human NSCLC cells and tumor formation in vivo

Authors:
- Zhiyuan Lou
- Bok‑Soon Lee
- Taekyu Ha
- Yanrui Xu
- Haeng‑Jun Kim
- Chul‑Ho Kim
- Seong‑Ho Lee
View Affiliations

Affiliations: Department of Nutrition and Food Science, College of Agriculture and Natural Resources, University of Maryland, College Park, MD 20742, USA, Department of Otolaryngology, School of Medicine, Ajou University, Yeongtong‑Gu, Suwon 16499, Republic of Korea
Published online on: July 12, 2018 https://doi.org/10.3892/or.2018.6560
Pages: 1734-1742

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the first leading cause of cancer‑related death in the United States. Non‑small cell lung cancer (NSCLC) is the most common type of lung cancer and is associated with a poor patient prognosis. Identification of promising molecular targets is required for the effective prevention and therapy of NSCLC. Epithelial‑specific ETS‑1 (ESE‑1) belongs to the superfamily of ETS transcription factors. The effect of ESE‑1 on tumorigenesis is controversial in several types of cancer while its role in lung cancer remains unknown. The present study was designed to investigate whether ESE‑1 expression affects tumorigenic activity using human NSCLC cells and a mouse xenograft model. ESE‑1 expression suppressed anchorage‑independent growth in soft agar assay and led to an increase in G1 arrest and apoptosis in human NSCLC cells. ESE‑1 expression suppressed the invasion and migration of human NSCLC cells. Western blot analysis, RT‑PCR and promoter assay indicated that ESE‑1 expression was transcriptionally downregulated by treatment of transforming growth factor (TGF)‑β, an EMT (epithelial‑mesenchymal transition) stimulator. The xenograft study indicated that ESE‑1 expression inhibited tumor formation and development. Our data demonstrated that ESE‑1 plays a key role as a tumor suppressor in human NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Schiller JH, Gandara DR, Goss GD and Vokes EE: Non-small-cell lung cancer: Then and now. J Clin Oncol. 31:981–983. 2013.doi: 10.1200/JCO.2012.47.5772. View Article : Google Scholar : PubMed/NCBI
3	Tymms MJ, Ng AY, Thomas RS, Schutte BC, Zhou J, Eyre HJ, Sutherland GR, Seth A, Rosenberg M, Papas T, et al: A novel epithelial-expressed ETS gene, ELF3: Human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer. Oncogene. 15:2449–2462. 1997. View Article : Google Scholar : PubMed/NCBI
4	Choi SG, Yi Y, Kim YS, Kato M, Chang J, Chung HW, Hahm KB, Yang HK, Rhee HH, Bang YJ and Kim SJ: A novel ets-related transcription factor, ERT/ESX/ESE-1, regulates expression of the transforming growth factor-β type II receptor. J Biol Chem. 273:110–117. 1998. View Article : Google Scholar : PubMed/NCBI
5	Chang CH, Scott GK, Kuo WL, Xiong X, Suzdaltseva Y, Park JW, Sayre P, Erny K, Collins C, Gray JW, et al: : ESX: A structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene. 14:1617–1622. 1997. View Article : Google Scholar : PubMed/NCBI
6	Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, Grall F, Dube A, Weiss A, Brown L, et al: PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem. 275:1216–1225. 2000. View Article : Google Scholar : PubMed/NCBI
7	Oettgen P, Alani RM, Barcinski MA, Brown L, Akbarali Y, Boltax J, Kunsch C, Munger K and Libermann TA: Isolation and characterization of a novel epithelium-specific transcription factor, ESE-1, a member of the ets family. Mol Cell Biol. 17:4419–4433. 1997. View Article : Google Scholar : PubMed/NCBI
8	Brembeck FH, Opitz OG, Libermann TA and Rustgi AK: Dual function of the epithelial specific ets transcription factor, ELF3, in modulating differentiation. Oncogene. 19:1941–1949. 2000. View Article : Google Scholar : PubMed/NCBI
9	Wang JL, Chen ZF, Chen HM, Wang MY, Kong X, Wang YC, Sun TT, Hong J, Zou W, Xu J, et al: Elf3 drives β-catenin transactivation and associates with poor prognosis in colorectal cancer. Cell Death Dis. 5:e12632014. View Article : Google Scholar : PubMed/NCBI
10	Yeung TL, Leung CS, Wong KK, Gutierrez-Hartmann A, Kwong J, Gershenson DM and Mok SC: ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget. 8:16951–16963. 2017. View Article : Google Scholar : PubMed/NCBI
11	Iwai S, Amekawa S, Yomogida K, Sumi T, Nakazawa M, Yura Y, Nishimune Y and Nozaki M: ESE-1 inhibits the invasion of oral squamous cell carcinoma in conjunction with MMP-9 suppression. Oral Dis. 14:144–149. 2008. View Article : Google Scholar : PubMed/NCBI
12	Lee SH, Bahn JH, Choi CK, Whitlock NC, English AE, Safe S and Baek SJ: ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol Cancer Ther. 7:3739–3750. 2008. View Article : Google Scholar : PubMed/NCBI
13	Longoni N, Sarti M, Albino D, Civenni G, Malek A, Ortelli E, Pinton S, Mello-Grand M, Ostano P, D'Ambrosio G, et al: ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-kappaB and drives prostate cancer progression. Cancer Res. 73:4533–4547. 2013. View Article : Google Scholar : PubMed/NCBI
14	Shatnawi A, Norris JD, Chaveroux C, Jasper JS, Sherk AB, McDonnell DP and Giguère V: ELF3 is a repressor of androgen receptor action in prostate cancer cells. Oncogene. 33:862–871. 2014. View Article : Google Scholar : PubMed/NCBI
15	Oliver JR, Kushwah R, Wu J, Pan J, Cutz E, Yeger H, Waddell TK and Hu J: Elf3 plays a role in regulating bronchiolar epithelial repair kinetics following Clara cell-specific injury. Lab Invest. 91:1514–1529. 2011. View Article : Google Scholar : PubMed/NCBI
16	Lee SH, Bahn JH, Whitlock NC and Baek SJ: Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways. Oncogene. 29:5182–5192. 2010. View Article : Google Scholar : PubMed/NCBI
17	Lee SH, Cekanova M and Baek SJ: Multiple mechanisms are involved in 6-gingerol-induced cell growth arrest and apoptosis in human colorectal cancer cells. Mol Carcinog. 47:197–208. 2008. View Article : Google Scholar : PubMed/NCBI
18	Ng AY, Waring P, Ristevski S, Wang C, Wilson T, Pritchard M, Hertzog P and Kola I: Inactivation of the transcription factor Elf3 in mice results in dysmorphogenesis and altered differentiation of intestinal epithelium. Gastroenterology. 122:1455–1466. 2002. View Article : Google Scholar : PubMed/NCBI
19	Wang H, Yu Z, Huo S, Chen Z, Ou Z, Mai J, Ding S and Zhang J: Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK signaling pathways in non-small cell lung cancer. Int J Biochem Cell Biol. 94:98–106. 2018. View Article : Google Scholar : PubMed/NCBI
20	Yang X and Lee SH: Identification of ESE1 as a β-Catenin Binding Protein. Anticancer Res. 36:2697–2703. 2016.PubMed/NCBI
21	Singla AK, Downey CM, Bebb GD and Jirik FR: Characterization of a murine model of metastatic human non-small cell lung cancer and effect of CXCR4 inhibition on the growth of metastases. Oncoscience. 2:263–271. 2015. View Article : Google Scholar : PubMed/NCBI
22	Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
23	Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
24	Zhang YE: Non-Smad pathways in TGF-beta signaling. Cell Res. 19:128–139. 2009. View Article : Google Scholar : PubMed/NCBI
25	Sinh ND, Endo K, Miyazawa K and Saitoh M: Ets1 and ESE1 reciprocally regulate expression of ZEB1/ZEB2, dependent on ERK1/2 activity, in breast cancer cells. Cancer Sci. 108:952–960. 2017. View Article : Google Scholar : PubMed/NCBI
26	Chang J, Lee C, Hahm KB, Yi Y, Choi SG and Kim SJ: Over-expression of ERT(ESX/ESE-1/ELF3), an ets-related transcription factor, induces endogenous TGF-beta type II receptor expression and restores the TGF-beta signaling pathway in Hs578t human breast cancer cells. Oncogene. 19:151–154. 2000. View Article : Google Scholar : PubMed/NCBI
27	Park SW, Do HJ, Ha WT, Han MH, Yang HM, Lee SH, Song H, Kim NH and Kim JH: Transcriptional regulation of OCT4 by the ETS transcription factor ESE-1 in NCCIT human embryonic carcinoma cells. Biochem Biophys Res Commun. 450:984–990. 2014. View Article : Google Scholar : PubMed/NCBI